Skip to main content
. 2019 Dec 4;11(3):630–643. doi: 10.1093/advances/nmz120

TABLE 2.

Pooled risk estimates of bladder cancer risk associated with high versus low carotenoid intake and circulating carotenoid concentrations in adults as defined in each original study: overall and subgroup analysis1

Test for heterogeneity of RRs
Factors stratified Studies, n Participants, n RR (95% CI) I2 Parameter, %2 χ2 P value P 3
Dietary intake
 Total carotenoids
  All studies 11 366,246 0.88 (0.76, 1.03) 74.5 39.26 <0.0001
  Sex 0.84
   Men 10 172,261 0.85 (0.72, 0.99) 71.0 31.07 <0.0001
   Women 6 193,985 0.86 (0.67, 1.09) 79.6 24.47 <0.0001
  Study design <0.0001
   Case-control 7 12,925 0.77 (0.63, 0.94) 64.7 16.98 0.009
   Cohort 4 353,321 1.09 (0.93, 1.27) 56.8 6.95 0.074
  Origin of the participants 0.02
   Europeans 3 32,410 1.05 (0.92, 1.20) 39.7 3.32 0.19
   Americans 8 333,836 0.80 (0.64, 1.004) 76.9 30.32 <0.0001
  Study quality <0.0001
   7 stars 3 117,692 1.13 (0.95, 1.36) 51.7 4.14 0.13
   8+ stars 8 248,554 0.81 (0.68, 0.95) 63.4 19.13 0.008
 α-carotene 9 364,699 0.94 (0.80, 1.09) 46.1 16.71 0.053
 β-carotene 14 447,351 0.95 (0.88, 1.03) 35.9 21.85 0.08
 β-cryptoxanthin 7 360,758 0.90 (0.80, 1.02) 44.3 12.57 0.08
 Lutein and zeaxanthin 8 362,365 0.91 (0.76, 1.10) 51.5 16.48 0.04
 Lycopene 8 362,365 0.99 (0.87, 1.12) 13.2 9.22 0.32
Circulating carotenoid concentrations
  Total carotenoids 3 2014 0.36 (0.12, 1.07) 85.2 13.48 0.001
  α-carotene 3 2191 0.52 (0.21, 1.27) 67.1 6.08 0.048
  β-carotene 4 2296 0.67 (0.28, 1.62) 74.0 11.53 0.009
  β-cryptoxanthin 3 2191 0.64 (0.22, 1.86) 69.6 6.57 0.04
  Lutein and zeaxanthin 3 2191 0.53 (0.33, 0.84) 34.0 6.06 0.19
  Lycopene 4 2296 0.76 (0.39, 1.49) 49.0 5.88 0.12
Dietary supplementation
  β-carotene 2 132,607 0.94 (0.70, 1.26) 0.0 0.1 0.75
1

The associations of carotenoid intakes/circulating carotenoid concentrations with bladder cancer risk were estimated using DerSimonian and Laird random-effect (15) models by comparing the highest with the lowest (the referent) category.

2

Heterogeneity among studies was evaluated by the Cochran Q test (16, 17) and the I2 parameter, which represents the percentage of total variation across studies that is attributable to heterogeneity rather than chance (49).

3

P values test for the homogeneity comparison between subgroups.